Close Asset Management’s Autolus Therapeutics AUTL Stock Holding History

Close Asset Management’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10K	Hold	6,300	–	–	﹤0.01%	224
2026 Q1	$9K	Hold	6,300	–	–	﹤0.01%	228
2025 Q4	$13K	Hold	6,300	–	–	﹤0.01%	222
2025 Q3	$10K	Buy	6,300 +3,000	+91%	+$5.86K	﹤0.01%	227
2025 Q2	$8K	Buy	3,300 +2,800	+560%	+$4.63K	﹤0.01%	221
2025 Q1	$1K	Hold	500	–	–	﹤0.01%	240
2024 Q4	$1K	Hold	500	–	–	﹤0.01%	238
2024 Q3	$2K	Hold	500	–	–	﹤0.01%	246
2024 Q2	$2K	Hold	500	–	–	﹤0.01%	242
2024 Q1	$3K	Hold	500	–	–	﹤0.01%	240
2023 Q4	$3K	Hold	500	–	–	﹤0.01%	225
2023 Q3	$1K	Hold	500	–	–	﹤0.01%	232
2023 Q2	$1K	Hold	500	–	–	﹤0.01%	242
2023 Q1	$1K	Buy	+500	New	+$978	﹤0.01%	230

Other funds holding AUTL

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Close Asset Management's AUTL Position: Q2 2026 in Review

Close Asset Management held its Autolus Therapeutics (AUTL) position steady in Q2 2026 at 6,300 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #224.

Close Asset Management first reported a position in AUTL in Q1 2023 and has held it in 14 quarters since. The position peaked at $13K in Q4 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

Close Asset Management held 6,300 shares of Autolus Therapeutics worth $10K as of Q2 2026.
Close Asset Management left its Autolus Therapeutics share count unchanged in Q2 2026.
Autolus Therapeutics made up ﹤0.01% of Close Asset Management's portfolio in Q2 2026, its #224 holding.
Close Asset Management first reported a position in Autolus Therapeutics in Q1 2023 and has held it in 14 quarters since.
Close Asset Management's Autolus Therapeutics position peaked at $13K in Q4 2025.
84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Close Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.